Expressing support for the recognition of "Hidradenitis Suppurativa Awareness Week".
- Bill Number
- H.Res. 484
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-06: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-07-11T08:05:41Z
AI-Generated Summary
Purpose
This House Resolution (H. Res. 484) aims to express the U.S. House of Representatives' support for designating the first week of June as "Hidradenitis Suppurativa Awareness Week." It seeks to raise public awareness about Hidradenitis Suppurativa (HS), a chronic inflammatory skin disease, and encourage actions to improve diagnosis, treatment, and support for affected individuals.
Key Provisions
- Background on HS: The resolution outlines HS as a condition affecting about 3.3 million people in the U.S., causing painful nodules, abscesses, scarring, and emotional distress. It highlights issues like high misdiagnosis rates (75% of cases after age 25), links to high suicide rates among skin diseases, and impacts on work, relationships, and daily life.
- Current Challenges: Notes limited treatment options (only three FDA-approved biologic therapies as of June 1, 2025), the need for more research on disease causes, biomarkers, and outcomes, and how delayed care leads to higher costs and emergency visits.
- Resolution Actions:
- Supports recognition of HS Awareness Week to boost understanding and progress toward curing HS.
- Emphasizes the importance of:
- Increasing awareness and education for the public and health professionals.
- Promoting early and accurate diagnosis through better screening and culturally sensitive care.
- Funding research on HS causes, treatment effectiveness, and long-term results.
- Speeding up new treatments and improving access to existing ones.
- Addressing care disparities and enhancing quality of life for patients and caregivers.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no changes to existing laws or statutes. It serves as a symbolic statement of congressional support rather than enforceable legislation.
Potential Impacts
- On Citizens: Could increase public knowledge of HS, leading to earlier diagnoses, reduced stigma, and better support for the 3.3 million affected Americans, including fewer emergency visits and improved mental health outcomes.
- On Government Agencies: May encourage agencies like the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to prioritize HS research and access to therapies, potentially influencing federal health policies without mandating action.
- On International Relations: Minimal direct impact, though heightened U.S. awareness could indirectly support global health discussions on rare diseases.
- Broader Effects: Might inspire state-level initiatives or private sector involvement in HS care, reducing healthcare costs from delayed treatments.
Main Stakeholders Affected
- Patients and Caregivers: Individuals with HS (primarily diagnosed in young adulthood) and their families, who face physical pain, emotional distress, and barriers to care.
- Healthcare Professionals: Doctors, dermatologists, and mental health providers, who need better education for timely diagnosis and treatment.
- Researchers and Pharmaceutical Companies: Benefit from calls for more biomedical research and new therapies.
- Policymakers and Advocacy Groups: Congress and organizations focused on chronic diseases, who could use this to advocate for funding and policy reforms.
Notable Legal, Constitutional, or Political Implications
- Legal: No binding effects; it does not create new rights, obligations, or regulations, aligning with the role of resolutions in expressing congressional sentiment.
- Constitutional: Neutral, as it falls within Congress's free speech and oversight powers on public health issues without infringing on individual rights.
- Political: Demonstrates bipartisan attention to underrecognized health conditions, potentially building momentum for future funding in health appropriations bills. It highlights disparities in care, which could influence debates on healthcare equity without partisan bias.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-06-06: Referred to the House Committee on Energy and Commerce.
- 2025-06-06: Submitted in House
- 2025-06-06: Submitted in House
Bill Versions
- Expressing support for the recognition of "Hidradenitis Suppurativa Awareness Week". — issued 2025-06-06 — PDF (3 pages)